Biotechnology company EpiBiologics has appointed Dr Ann Lee-Karlon as CEO, president and a member of its board.
Lee-Karlon will handle activities related to the expansion of the EpiTAC platform, a modular antibody-based system. She will establish partnerships and create a bispecific antibody protein degrader therapeutics pipeline.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Lee-Karlon previously worked as chief operating officer at Altos Labs. She has also served as senior vice-president at Genentech.
Lee-Karlon stated: “EpiBiologics has developed a groundbreaking platform to target membrane and extracellular proteins, leveraging a novel atlas of tissue-specific degrader antibodies.
“Targeted extracellular protein degradation represents a new therapeutic modality with a wide range of applications, including cancer, immunology and neurological diseases.”
EpiBiologics has also raised $23m in a new Series A financing round, taking the total Series A funds to $73m.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNew investors Digitalis Ventures and Taiho Ventures and current investor Codon Capital provided the latest financing.
EpiBiologics was launched in March 2023 with Series A financing of $50m from investors Polaris Partners, Mubadala Capital, Vivo Capital and GV.
The EpiTAC platform aids in the tissue-specific breakdown of disease-causing membrane and extracellular proteins.
Digitalis Ventures partner Samuel Bjork stated: “EpiBiologics has made tremendous progress with its leading-edge EpiTAC platform, which will unravel the underlying intricacies of disease biology to build precision therapeutics.”
